Why Biopharma Must Rethink Supply Chains, Manufacturing and Regulatory Readiness

Shortages Expose What Companies Did Not Know

Biopharmaceutical companies once treated operations largely as a support function. That distinction is increasingly difficult to maintain. Supply-chain design now affects competitive strategy, public policy, national security, and patient safety. Decisions about sourcing, manufacturing, inventory, and distribution therefore require sustained attention from senior leadership.

For many years, companies organized global production networks primarily around cost and quality, with limited reserves for disruption. The emerging model is more regional, includes greater redundancy, and is generally more expensive. Trade policy, sanctions, local-content requirements, and industrial policy are encouraging manufacturers to reconsider where materials originate, where products are made, and where reserve capacity is located. Even when management would prefer a single global network, policy and geopolitical risk may require a more regional structure.

Operational resilience has become a strategic concern because weaknesses in supply systems continue to affect patient care. The U.S. Food and Drug Administration (FDA) identifies manufacturing and quality problems, production delays, and product discontinuations as causes of drug shortages.¹ These causes demonstrate that supply risk often develops within the production system itself rather than arising only from unexpected external events.

Market structure can make shortages more severe. The American Society of Health-System Pharmacists (ASHP) reports that 48% of new shortages in 2026 involved products supplied by only one manufacturer.² Hospitals and health systems have few alternatives when the sole plant or supplier experiences a problem. The U.S. Pharmacopeia reported that the number of shortages declined in 2025, but those that remained lasted longer. It linked this persistence to low prices, manufacturing complexity, geographic concentration, and quality concerns.³

Shortages also reveal incomplete knowledge of supply networks. A medicine described as having two suppliers may still depend on the same upstream chemical process, region, or transportation route. A network that appears diversified in a summary report may remain concentrated at a less visible level. Companies therefore need information about dependencies below their direct suppliers, not simply a count of approved sources.

Regionalization Comes with a Cost

Returning production to the home market or moving it to politically aligned countries can reduce some geopolitical exposure, but these strategies require substantial time and investment. New facilities need capital, specialized employees, regulatory approval, and the transfer and validation of manufacturing processes. The challenge is especially significant for biologics and complex sterile products, where small process changes can result in the loss of an expensive batch and may affect both supply and organizational reputation.

Resilience therefore involves more than identifying backup suppliers. Companies must determine which products require redundant capacity, which markets need local or regional manufacturing, and which low-margin medicines cannot support an additional source without changes in pricing or public policy. Some products cannot absorb the full cost of resilience within their individual financial structure.

Broader supply security may consequently require cooperation among manufacturers, payers, health systems, and governments. Such cooperation may include purchasing commitments, incentives for reserve capacity, or policies that recognize the additional cost of maintaining multiple qualified sources. The central challenge is to allocate resilience investment where failure would create the greatest harm to patients and the health system.

Modern Plants Need Better Data, Not Just Better Steel

Many pharmaceutical facilities still rely on older equipment and information systems that do not communicate effectively. Managers may assemble operational information from spreadsheets, periodic reports, and locally developed workarounds. These arrangements were more manageable when products and supply networks were less complex. They create greater risk today because equipment failure, quality deviations, maintenance delays, and supplier disruptions can quickly affect a tightly scheduled manufacturing network.

Research on digital transformation indicates that artificial intelligence can improve demand forecasting, inventory management, and supply-chain risk analysis. It also emphasizes continuing constraints related to regulation and data governance.⁴ A digital system is useful only when the underlying information is complete, consistent, and appropriately controlled.

Clinical development adds further operational complexity. EY reported that more than 550,000 active clinical studies were registered across 228 countries as of mid-2025. It also noted that clinical-trial supply chains were under pressure from advanced therapies, decentralized trial designs, and expanding regulatory requirements.⁵

The practical value of digital operations is straightforward. Better forecasts can guide the allocation of limited supplies. Centralized monitoring can reveal where inventory is delayed or unavailable. Connected manufacturing data can identify process changes before they become formal deviations. However, technology cannot correct a poorly designed operating model by itself. When data are fragmented or weakly governed, automation may spread errors more quickly than manual processes.

Compliance Is Becoming Continuous

Regulatory compliance is also changing. Organizations can no longer depend on brief periods of inspection preparation while routine operations rely on disconnected records. As the volume of data increases and regulatory expectations develop, compliance increasingly requires continuous monitoring, reliable digital systems, and strong control of source data. Paper records and spreadsheets may retain limited uses, but they create risk when they are the primary means of managing complex processes.

This change has strategic consequences. Product launches, technology transfers, and investments in manufacturing sites depend partly on whether a company can produce accurate, timely, and inspection-ready information at scale. Compliance is therefore becoming an operating capability rather than a documentation activity completed after decisions have been made. Treating it as a downstream requirement can lead to remediation expense as well as delays in responding to scientific, market, or supply changes.

Resilience Is Becoming Part of the Value Proposition

Investors, regulators, health systems, and patients increasingly want to know whether a company can manufacture and deliver its products reliably. Between 2026 and 2030, this question may become nearly as important as the quality of the underlying science. In a market affected by shortages, geopolitical uncertainty, and closer oversight, operational resilience can reduce risk, protect revenue, preserve continuity of care, and strengthen public confidence.

Key Issues at a Glance

Geopolitics is regionalizing pharmaceutical supply

Tariffs, industrial policy and concentrated suppliers are replacing one global network with interconnected regional networks.

• API and KSM Sequestered: Hidden sub-tier dependence creates shortage and geopolitical exposure, especially in Asia-linked supply. API = Active Pharmaceutical Ingredient; KSM = Key Starting Material.
• Trade and Localization Policies: Tariffs, sanctions and local-content rules increase cost and complicate transfer pricing and supply decisions.
• Reshoring economics: New capacity requires capital, specialized labor and complex regulatory technology transfer.

Quality, capacity and shortages require modern operations

Plants must become more flexible, connected and efficient without disrupting validated operations or product supply.

• Aging Assets and Weak Connectivity: Legacy equipment limits real-time visibility and integrated automation across validated processes.
• Deviation and Batch-loss Risks: Process drift can destroy expensive batches, particularly for biologics and high-value APIs.
• Thin Margins and No Redundancy: Low-margin products often cannot support backup capacity or sustained quality investment.

Regulatory compliance is becoming continuous and digital

Changing standards and expanding data volumes make periodic, document-centered compliance increasingly inadequate.

• Shifting Evidence Standards: Regulatory priorities and submission expectations create uncertainty for investment / launch planning.
• Data Integrity Gaps: Paper, spreadsheets and disconnected systems struggle to meet ALCOA+ expectations.
• Digital Reporting Burden: Legacy environments make consistent, timely and inspection-ready reporting difficult.

Frequently Asked Questions

References

1. U.S. Food and Drug Administration. “Drug Shortages.”
2. American Society of Health-System Pharmacists. “Drug Shortages Statistics.”
3. Regulatory Affairs Professionals Society. “USP: Drug Shortages Declined in 2025 but Are Lasting Longer.“
4. Exploratory Research and Hypothesis in Medicine. “Digital Transformation in Pharmaceuticals: The Impact of AI on Supply Chain Management.”
5. EY. “How Digital, AI-Enabled Supply Chains Can Strengthen Clinical Trials.”